Facet Biotech (FACT) says Biogen Idec's (NASDAQ:BIIB) increased bid of $17.50/share is still too...

Facet Biotech (FACT) says Biogen Idec's (NASDAQ:BIIB) increased bid of $17.50/share is still too low, and not in shareholders' best interest. Facet notes other parties have also expressed interest in the company and its assets, and that it is allowing them, along with Biogen, to conduct due diligence.